Pharsight

Drugs with expired main patents

1. Abilify patents expiration

ABILIFY's oppositions filed in EPO
ABILIFY IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9359302 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(1 year, 7 months ago)

US8642760 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(1 year, 7 months ago)

US8580796 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(1 year, 7 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5006528 OTSUKA Carbostyril derivatives
Oct, 2014

(9 years ago)

US5006528

(Pediatric)

OTSUKA Carbostyril derivatives
Apr, 2015

(9 years ago)

US9358207 OTSUKA Flashmelt oral dosage formulation
Apr, 2020

(4 years ago)

US8518421 OTSUKA Flashmelt oral dosage formulation
Jan, 2021

(3 years ago)

US8518421

(Pediatric)

OTSUKA Flashmelt oral dosage formulation
Jul, 2021

(2 years ago)

US8642600 OTSUKA Method of treating autism
Jan, 2022

(2 years ago)

US9089567 OTSUKA Method of treating cognitive impairments and schizophrenias
Jan, 2022

(2 years ago)

US7053092 OTSUKA 5-HT1a receptor subtype agonist
Jan, 2022

(2 years ago)

US8642600

(Pediatric)

OTSUKA Method of treating autism
Jul, 2022

(1 year, 9 months ago)

US8642760

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Mar, 2023

(1 year, 2 months ago)

US8580796

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Mar, 2023

(1 year, 2 months ago)

US9387182 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Dec, 2023

(4 months ago)

US8017615 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2024

(22 days from now)

US8017615

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Dec, 2024

(6 months from now)

US9125939 OTSUKA Carbostyril derivatives and mood stabilizers for treating mood disorders
Jul, 2026

(2 years from now)

US8759350 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Mar, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Aug 27, 2011
Orphan Drug Exclusivity(ODE) Dec 12, 2021
M(M-137) Jun 09, 2017
New Indication(I-700) Dec 12, 2017
Orphan Drug Exclusivity(ODE-80) Dec 12, 2021
New Indication(I-633) Feb 16, 2014
New Indication(I-616) Nov 19, 2012

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 15 November, 2002

Treatment: Treatment of schizophrenia including maintaining stability in patients with schizophrenia; Treatment of irritability associated with autistic disorder; Treatment of schizophrenia; Treatment of major d...

Dosage: TABLET;ORAL; TABLET, ORALLY DISINTEGRATING;ORAL

How can I launch a generic of ABILIFY before it's drug patent expiration?
More Information on Dosage

ABILIFY family patents

Family Patents

2. Abilify Maintena Kit patents expiration

ABILIFY MAINTENA KIT's oppositions filed in EPO
ABILIFY MAINTENA KIT IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5006528 OTSUKA PHARM CO LTD Carbostyril derivatives
Oct, 2014

(9 years ago)

US8993761 OTSUKA PHARM CO LTD Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(1 year, 7 months ago)

US8399469 OTSUKA PHARM CO LTD Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2025

(1 year, 1 month from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5006528

(Pediatric)

OTSUKA PHARM CO LTD Carbostyril derivatives
Apr, 2015

(9 years ago)

US5006528 OTSUKA PHARM CO LTD Carbostyril derivatives
Apr, 2015

(9 years ago)

US9089567 OTSUKA PHARM CO LTD Method of treating cognitive impairments and schizophrenias
Jan, 2022

(2 years ago)

US8759351 OTSUKA PHARM CO LTD Methods for administering aripiprazole
Aug, 2023

(9 months ago)

US8338428 OTSUKA PHARM CO LTD Methods for administering aripiprazole
Aug, 2023

(9 months ago)

US8030313 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(4 months from now)

US7807680 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(4 months from now)

US8722679 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(4 months from now)

US8338427 OTSUKA PHARM CO LTD Methods for administering aripiprazole
Mar, 2025

(9 months from now)

US11400087 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(9 years from now)

US11344547 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(9 years from now)

US10980803 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(9 years from now)

US11154553 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(9 years from now)

US10525057 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Mar, 2034

(9 years from now)

US11648347 OTSUKA PHARM CO LTD Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient
Apr, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-746) Jul 27, 2020
New Dosage Form(NDF) Feb 28, 2016
M(M-150) Dec 05, 2017

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 28 February, 2013

Treatment: Treatment of schizophrenia; Use of aripiprazole in extended release injectable suspension; Use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia; Tr...

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of ABILIFY MAINTENA KIT before it's drug patent expiration?
More Information on Dosage

ABILIFY MAINTENA KIT family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Abilify Mycite Kit patents expiration

ABILIFY MYCITE KIT's oppositions filed in EPO
ABILIFY MYCITE KIT IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9359302 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(1 year, 7 months ago)

US8580796 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(1 year, 7 months ago)

US8642760 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(1 year, 7 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089567 OTSUKA Method of treating cognitive impairments and schizophrenias
Jan, 2022

(2 years ago)

US7053092 OTSUKA 5-HT1a receptor subtype agonist
Jan, 2022

(2 years ago)

US9387182 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Dec, 2023

(4 months ago)

US8017615 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2024

(22 days from now)

US11476952 OTSUKA Pharma-informatics system
Apr, 2026

(1 year, 11 months from now)

US9125939 OTSUKA Carbostyril derivatives and mood stabilizers for treating mood disorders
Jul, 2026

(2 years from now)

US7978064 OTSUKA Communication system with partial power source
Sep, 2026

(2 years from now)

US8759350 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Mar, 2027

(2 years from now)

US9444503 OTSUKA Active signal processing personal health signal receivers
Nov, 2027

(3 years from now)

US9119554 OTSUKA Pharma-informatics system
Dec, 2028

(4 years from now)

US9060708 OTSUKA Multi-mode communication ingestible event markers and systems, and methods of using the same
Mar, 2029

(4 years from now)

US9258035 OTSUKA Multi-mode communication ingestible event markers and systems, and methods of using the same
Mar, 2029

(4 years from now)

US8674825 OTSUKA Pharma-informatics system
Apr, 2029

(4 years from now)

US8956288 OTSUKA In-body power source having high surface area electrode
Jul, 2029

(5 years from now)

US10441194 OTSUKA Ingestible event marker systems
Jul, 2029

(5 years from now)

US8945005 OTSUKA Controlled activation ingestible identifier
Aug, 2029

(5 years from now)

US9433371 OTSUKA In-body device with virtual dipole signal amplification
Sep, 2029

(5 years from now)

US8718193 OTSUKA Active signal processing personal health signal receivers
Dec, 2029

(5 years from now)

US9149577 OTSUKA Body-associated receiver and method
Dec, 2029

(5 years from now)

US8847766 OTSUKA Pharma-informatics system
Mar, 2030

(5 years from now)

US8545402 OTSUKA Highly reliable ingestible event markers and methods for using the same
Apr, 2030

(5 years from now)

US8114021 OTSUKA Body-associated receiver and method
Jun, 2030

(6 years from now)

US11464423 OTSUKA In-body power source having high surface area electrode
Sep, 2030

(6 years from now)

US9941931 OTSUKA System for supply chain management
Nov, 2030

(6 years from now)

US8961412 OTSUKA In-body device with virtual dipole signal amplification
Nov, 2030

(6 years from now)

US8258962 OTSUKA Multi-mode communication ingestible event markers and systems, and methods of using the same
Nov, 2030

(6 years from now)

US8547248 OTSUKA Implantable zero-wire communications system
Dec, 2030

(6 years from now)

US11229378 OTSUKA Communication system with enhanced partial power source and method of manufacturing same
Jul, 2031

(7 years from now)

US9320455 OTSUKA Highly reliable ingestible event markers and methods for using the same
Dec, 2031

(7 years from now)

US10517507 OTSUKA Communication system with enhanced partial power source and method of manufacturing same
Jun, 2032

(8 years from now)

US9577864 OTSUKA Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance
Oct, 2033

(9 years from now)

US9268909 OTSUKA Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
Oct, 2033

(9 years from now)

US9787511 OTSUKA Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
Sep, 2034

(10 years from now)

US9270503 OTSUKA Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
Sep, 2034

(10 years from now)

US10097388 OTSUKA Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
Sep, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-150) Dec 05, 2017
New Indication(I-746) Jul 27, 2020

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: Treatment of schizophrenia; Adjunctive treatment of major depressive disorder (mdd); Acute treatment of manic and mixed episodes associated with bipolar i disorder; Method of using a receiver to ident...

Dosage: TABLET;ORAL

More Information on Dosage

ABILIFY MYCITE KIT family patents

Family Patents

4. Adasuve patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9687487 ALEXZA PHARMS Aerosol forming device for use in inhalation therapy
Oct, 2021

(2 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9440034 ALEXZA PHARMS Drug condensation aerosols and kits
Oct, 2021

(2 years ago)

US7090830 ALEXZA PHARMS Drug condensation aerosols and kits
Oct, 2021

(2 years ago)

US7585493 ALEXZA PHARMS Thin-film drug delivery article and method of use
Oct, 2021

(2 years ago)

US7078020 ALEXZA PHARMS Delivery of antipsychotics through an inhalation route
Oct, 2021

(2 years ago)

US7601337 ALEXZA PHARMS Delivery of antipsychotics through an inhalation route
Oct, 2021

(2 years ago)

US8074644 ALEXZA PHARMS Method of forming an aerosol for inhalation delivery
Oct, 2021

(2 years ago)

US8955512 ALEXZA PHARMS Method of forming an aerosol for inhalation delivery
Oct, 2021

(2 years ago)

US9439907 ALEXZA PHARMS Method of forming an aerosol for inhalation delivery
Oct, 2021

(2 years ago)

US8173107 ALEXZA PHARMS Delivery of antipsychotics through an inhalation route
Oct, 2021

(2 years ago)

US8235037 ALEXZA PHARMS Drug condensation aerosols and kits
Oct, 2021

(2 years ago)

US7052679 ALEXZA PHARMS Delivery of antipsychotics through an inhalation route
Mar, 2022

(2 years ago)

US6716416 ALEXZA PHARMS Delivery of antipsychotics through an inhalation route
May, 2022

(2 years ago)

US9370629 ALEXZA PHARMS Self-contained heating unit and drug-supply unit employing same
May, 2024

(4 days ago)

US8991387 ALEXZA PHARMS Self-contained heating unit and drug-supply unit employing same
May, 2024

(3 days ago)

US7458374 ALEXZA PHARMS Method and apparatus for vaporizing a compound
Aug, 2024

(2 months from now)

US7537009 ALEXZA PHARMS Method of forming an aerosol for inhalation delivery
Oct, 2024

(5 months from now)

US8387612 ALEXZA PHARMS Self-contained heating unit and drug-supply unit employing same
Oct, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Dec 21, 2015

Drugs and Companies using LOXAPINE ingredient

Market Authorisation Date: 21 December, 2012

Treatment: Adasuve is a typical antipsychotic indicated for the acute treatment of agitation associated with schizophrenia or bipolar i disorder in adults

Dosage: POWDER;INHALATION

More Information on Dosage

ADASUVE family patents

Family Patents

5. Addyi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7420057 SPROUT PHARMS Stable polymorph of flibanserin
Aug, 2022

(1 year, 9 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9468639 SPROUT PHARMS Treating sexual desire disorders with flibanserin
Oct, 2022

(1 year, 7 months ago)

US8227471 SPROUT PHARMS Treating sexual desire disorders with flibanserin
May, 2023

(1 year, 16 days ago)

US7151103 SPROUT PHARMS Method of treating female hypoactive sexual desire disorder with flibanserin
May, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 18, 2020

Drugs and Companies using FLIBANSERIN ingredient

NCE-1 date: 19 August, 2019

Market Authorisation Date: 18 August, 2015

Treatment: Use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd)

Dosage: TABLET;ORAL

More Information on Dosage

ADDYI family patents

Family Patents

6. Adlyxin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE45313 SANOFI-AVENTIS US Exendin variant peptides
Jul, 2020

(3 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9855388 SANOFI-AVENTIS US Dosing and drive mechanism for drug delivery device
Apr, 2029

(4 years from now)

US8915888 SANOFI-AVENTIS US Dosing and drive mechanism for drug delivery device
Jun, 2030

(6 years from now)

US9981013 SANOFI-AVENTIS US Use of AVE0010 for the treatment of diabetes mellitus type 2
Aug, 2030

(6 years from now)

US9707176 SANOFI-AVENTIS US Pharmaceutical composition comprising a GLP-1 agonist and methionine
Nov, 2030

(6 years from now)

US10028910 SANOFI-AVENTIS US Pharmaceutical composition comprising a GLP-1-agonist and methionine
Nov, 2030

(6 years from now)

US8475414 SANOFI-AVENTIS US Medication delivery device and method for operating a medication delivery device
Dec, 2030

(6 years from now)

US9308329 SANOFI-AVENTIS US Medication delivery device and method for operating a medication delivery device
Dec, 2030

(6 years from now)

US8882721 SANOFI-AVENTIS US Drive assembly suitable for use in a drug delivery device and drug delivery device
Jun, 2031

(7 years from now)

US9084853 SANOFI-AVENTIS US Drive mechanism for a drug delivery device and drug delivery device
Oct, 2031

(7 years from now)

US9511193 SANOFI-AVENTIS US Assembly and indicator for a drug delivery device
Jan, 2032

(7 years from now)

US9440029 SANOFI-AVENTIS US Drive mechanism for a drug delivery device and drug delivery device
Jan, 2032

(7 years from now)

US9072836 SANOFI-AVENTIS US Drive mechanism for a drug delivery device and drug delivery device
Mar, 2032

(7 years from now)

US9821032 SANOFI-AVENTIS US Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
May, 2032

(7 years from now)

US9408893 SANOFI-AVENTIS US Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
Aug, 2032

(8 years from now)

US10201663 SANOFI-AVENTIS US Assembly for a drug delivery device
Mar, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 27, 2021

Drugs and Companies using LIXISENATIDE ingredient

NCE-1 date: 27 July, 2020

Market Authorisation Date: 27 July, 2016

Treatment: Improvement in glycemic control in type 2 diabetes mellitus patients by use of a pen injector; Improvement of glycemic control in type 2 diabetes patients by administering a starting dose of 10 mcg fo...

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

ADLYXIN family patents

Family Patents

7. Aggrastat patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5733919 MEDICURE Compositions for inhibiting platelet aggregation
Oct, 2016

(7 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5733919 MEDICURE Compositions for inhibiting platelet aggregation
Oct, 2016

(7 years ago)

US5972967 MEDICURE Compositions for inhibiting platelet aggregation
Oct, 2016

(7 years ago)

US5965581 MEDICURE Compositions for inhibiting platelet aggregation
Oct, 2016

(7 years ago)

US5978698 MEDICURE Angioplasty procedure using nonionic contrast media
Oct, 2017

(6 years ago)

US6136794 MEDICURE Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
Jan, 2019

(5 years ago)

US6770660 MEDICURE Method for inhibiting platelet aggregation
May, 2023

(1 year, 24 days ago)

Drugs and Companies using TIROFIBAN HYDROCHLORIDE ingredient

Market Authorisation Date: 14 May, 1998

Treatment: A dosing regimen of aggrastat (tirofiban hydrochloride)(25mcg/kg followed by 0.15mcg/kg/min infusion) to reduce the rate of thrombotic coronary events associated with acute coronary syndrome (acs) in ...

Dosage: SOLUTION;INJECTION; INJECTABLE;INJECTION

How can I launch a generic of AGGRASTAT before it's drug patent expiration?
More Information on Dosage

AGGRASTAT family patents

Family Patents

8. Arcapta Neohaler patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8658673 NOVARTIS BETA2-adrenoreceptor agonists
Jun, 2020

(3 years ago)

US8796307 NOVARTIS Beta2-adrenoreceptor agonists
Jun, 2020

(3 years ago)

US6878721 NOVARTIS Beta2-adrenoceptor agonists
Feb, 2025

(9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8067437 NOVARTIS Beta-2-adrenoreceptor agonists
Jun, 2020

(3 years ago)

US8479730 NOVARTIS Inhaler device
Oct, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 01, 2016

Drugs and Companies using INDACATEROL MALEATE ingredient

NCE-1 date: 02 July, 2015

Market Authorisation Date: 01 July, 2011

Treatment: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema

Dosage: POWDER;INHALATION

More Information on Dosage

ARCAPTA NEOHALER family patents

Family Patents

9. Arnuity Ellipta patents expiration

ARNUITY ELLIPTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7101866 GLAXOSMITHKLINE Anti-inflammatory androstane derivative
Aug, 2021

(2 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5873360 GLAXOSMITHKLINE Inhalation device
Feb, 2016

(8 years ago)

US7629335 GLAXOSMITHKLINE Anti-inflammatory androstane derivative
Aug, 2021

(2 years ago)

US9333310 GLAXOSMITHKLINE Medicament dispenser
Oct, 2027

(3 years from now)

US8113199 GLAXOSMITHKLINE Counter for use with a medicament dispenser
Oct, 2027

(3 years from now)

US8161968 GLAXOSMITHKLINE Medicament dispenser
Feb, 2028

(3 years from now)

US9333310

(Pediatric)

GLAXOSMITHKLINE Medicament dispenser
Apr, 2028

(3 years from now)

US8113199

(Pediatric)

GLAXOSMITHKLINE Counter for use with a medicament dispenser
Apr, 2028

(3 years from now)

US8161968

(Pediatric)

GLAXOSMITHKLINE Medicament dispenser
Aug, 2028

(4 years from now)

US8201556 GLAXOSMITHKLINE Medicament dispenser
Feb, 2029

(4 years from now)

US8534281 GLAXOSMITHKLINE Manifold for use in medicament dispenser
Mar, 2030

(5 years from now)

US8534281

(Pediatric)

GLAXOSMITHKLINE Manifold for use in medicament dispenser
Sep, 2030

(6 years from now)

US8746242 GLAXOSMITHKLINE Medicament dispenser
Oct, 2030

(6 years from now)

US8746242

(Pediatric)

GLAXOSMITHKLINE Medicament dispenser
Apr, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-290) Mar 01, 2026
New Strength(NS) May 17, 2021
New Patient Population(NPP) May 17, 2021
New Product(NP) Aug 20, 2017

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 17 May, 2018

Treatment: Indicated for the once-daily maintenance treatment of asthma as prophylactic therapy in patients aged 12 years of age and older

Dosage: POWDER;INHALATION

More Information on Dosage

ARNUITY ELLIPTA family patents

Family Patents

10. Auryxia patents expiration

AURYXIA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9328133 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(3 months ago)

US9757416 KERYX BIOPHARMS Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(3 months ago)

US8338642 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(3 months ago)

US7767851 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(3 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5753706 KERYX BIOPHARMS Methods for treating renal failure
Feb, 2022

(2 years ago)

US9050316 KERYX BIOPHARMS Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(3 months ago)

US8846976 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(3 months ago)

US8901349 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(3 months ago)

US8609896 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(3 months ago)

US8299298 KERYX BIOPHARMS Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
Feb, 2024

(3 months ago)

US8754258 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(3 months ago)

US8754257 KERYX BIOPHARMS Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(3 months ago)

US8093423 KERYX BIOPHARMS Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
Apr, 2026

(1 year, 10 months from now)

US10300039 KERYX BIOPHARMS Ferric citrate dosage forms
Jul, 2030

(6 years from now)

US9387191 KERYX BIOPHARMS Ferric citrate dosage forms
Jul, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-790) Nov 06, 2020

Drugs and Companies using FERRIC CITRATE ingredient

Market Authorisation Date: 05 September, 2014

Treatment: Control of serum phosphorous levels; Control of serum phosphorus levels

Dosage: TABLET;ORAL

More Information on Dosage

AURYXIA family patents

Family Patents

11. Axumin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5808146 BLUE EARTH Amino acid analogs for tumor imaging
Nov, 2020

(3 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9387266 BLUE EARTH Precursor compound of radioactive halogen-labeled organic compound
Nov, 2026

(2 years from now)

US10953112 BLUE EARTH Precursor compound of radioactive halogen-labeled organic compound
Nov, 2026

(2 years from now)

US10010632 BLUE EARTH Precursor compound of radioactive halogen-labeled organic compound
Nov, 2026

(2 years from now)

US10124079 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(11 years from now)

US10716868 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(11 years from now)

US10967077 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(11 years from now)

US10933147 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 27, 2021

Drugs and Companies using FLUCICLOVINE F-18 ingredient

NCE-1 date: 27 May, 2020

Market Authorisation Date: 27 May, 2016

Treatment: Method of diagnosing tumors using positron emission tomography; Positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate speci...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

AXUMIN family patents

Family Patents

12. Daliresp patents expiration

DALIRESP's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5712298 ASTRAZENECA Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
Jan, 2020

(4 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5712298 ASTRAZENECA Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
Jan, 2015

(9 years ago)

US8431154 ASTRAZENECA Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
Feb, 2023

(1 year, 3 months ago)

US9468598 ASTRAZENECA Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
Feb, 2023

(1 year, 3 months ago)

US8536206 ASTRAZENECA Process for the preparation of roflumilast
Mar, 2024

(2 months ago)

US8604064 ASTRAZENECA Process for the preparation of roflumilast
Mar, 2024

(2 months ago)

US8618142 ASTRAZENECA Process for the preparation of roflumilast
Mar, 2024

(2 months ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-208) Aug 31, 2020
New Strength(NS) Jan 23, 2021
New Dosing Schedule(D-171) Jan 23, 2021
New Chemical Entity Exclusivity(NCE) Feb 28, 2016

Drugs and Companies using ROFLUMILAST ingredient

NCE-1 date: 28 February, 2015

Market Authorisation Date: 23 January, 2018

Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations

Dosage: TABLET;ORAL

How can I launch a generic of DALIRESP before it's drug patent expiration?
More Information on Dosage

DALIRESP family patents

Family Patents

13. Dexilant patents expiration

DEXILANT's oppositions filed in EPO
Can you believe DEXILANT received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9145389 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(3 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6939971 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(3 years ago)

US6462058 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(3 years ago)

US6664276 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(3 years ago)

US7285668 TAKEDA PHARMS USA Process for the crystallization of (R)- or (S)-lansoprazole
Jun, 2020

(3 years ago)

US7285668

(Pediatric)

TAKEDA PHARMS USA Process for the crystallization of (R)- or (S)-lansoprazole
Dec, 2020

(3 years ago)

US6462058

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Dec, 2020

(3 years ago)

US6939971

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Dec, 2020

(3 years ago)

US6664276

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Dec, 2020

(3 years ago)

US8784885 TAKEDA PHARMS USA Controlled release preparation
Oct, 2023

(7 months ago)

US8722084 TAKEDA PHARMS USA Controlled release preparation
Oct, 2023

(7 months ago)

US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(a month ago)

US8722084

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(a month ago)

US8461187 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(1 year, 7 months from now)

US9238029 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(1 year, 7 months from now)

US9011926 TAKEDA PHARMS USA Method for producing granules
Feb, 2026

(1 year, 9 months from now)

US8461187

(Pediatric)

TAKEDA PHARMS USA Multiple PPI dosage form
Jul, 2026

(2 years from now)

US7790755 TAKEDA PHARMS USA Controlled release preparation
Aug, 2026

(2 years from now)

US8105626 TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount
Sep, 2026

(2 years from now)

US7790755

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Feb, 2027

(2 years from now)

US8105626

(Pediatric)

TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount
Mar, 2027

(2 years from now)

US8871273 TAKEDA PHARMS USA Method for producing granules
Jan, 2028

(3 years from now)

US8173158 TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food
Mar, 2030

(5 years from now)

US8173158

(Pediatric)

TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food
Sep, 2030

(6 years from now)

US9233103 TAKEDA PHARMS USA Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
Mar, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 30, 2012
New Patient Population(NPP) Jul 08, 2019
Pediatric Exclusivity(PED) Jul 30, 2012

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: Healing of all grades of erosive esophagitis (ee) for up to 8 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months; Treatment of heartburn associated with non-erosive gastroesophagea...

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of DEXILANT before it's drug patent expiration?
More Information on Dosage

DEXILANT family patents

Family Patents

14. Dexilant Solutab patents expiration

DEXILANT SOLUTAB's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6462058 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(3 years ago)

US9145389 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(3 years ago)

US7285668 TAKEDA PHARMS USA Process for the crystallization of (R)- or (S)-lansoprazole
Jun, 2020

(3 years ago)

US6664276 TAKEDA PHARMS USA Benzimidazole compound crystal
Jan, 2023

(1 year, 3 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7399485 TAKEDA PHARMS USA Rapidly Disintegrable solid preparation
May, 2018

(6 years ago)

US7399485

(Pediatric)

TAKEDA PHARMS USA Rapidly Disintegrable solid preparation
Nov, 2018

(5 years ago)

US6328994 TAKEDA PHARMS USA Orally disintegrable tablets
May, 2019

(5 years ago)

US6238994 TAKEDA PHARMS USA Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article
May, 2019

(5 years ago)

US7875292 TAKEDA PHARMS USA Orally disintegrable tablets
May, 2019

(5 years ago)

US7431942 TAKEDA PHARMS USA Orally disintegrable tablets
May, 2019

(5 years ago)

US6238994

(Pediatric)

TAKEDA PHARMS USA Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article
Nov, 2019

(4 years ago)

US6328994

(Pediatric)

TAKEDA PHARMS USA Orally disintegrable tablets
Nov, 2019

(4 years ago)

US7875292

(Pediatric)

TAKEDA PHARMS USA Orally disintegrable tablets
Nov, 2019

(4 years ago)

US7431942

(Pediatric)

TAKEDA PHARMS USA Orally disintegrable tablets
Nov, 2019

(4 years ago)

US6939971 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(3 years ago)

US6939971

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Dec, 2020

(3 years ago)

US7285668

(Pediatric)

TAKEDA PHARMS USA Process for the crystallization of (R)- or (S)-lansoprazole
Dec, 2020

(3 years ago)

US6462058

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Dec, 2020

(3 years ago)

US6664276

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Jul, 2023

(9 months ago)

US8784885 TAKEDA PHARMS USA Controlled release preparation
Oct, 2023

(7 months ago)

US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(a month ago)

US9238029 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(1 year, 7 months from now)

US8461187 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(1 year, 7 months from now)

US9011926 TAKEDA PHARMS USA Method for producing granules
Feb, 2026

(1 year, 9 months from now)

US8461187

(Pediatric)

TAKEDA PHARMS USA Multiple PPI dosage form
Jul, 2026

(2 years from now)

US8871273 TAKEDA PHARMS USA Method for producing granules
Jan, 2028

(3 years from now)

US8871273

(Pediatric)

TAKEDA PHARMS USA Method for producing granules
Jul, 2028

(4 years from now)

US9241910 TAKEDA PHARMS USA Orally-disintegrating solid preparation
Mar, 2029

(4 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 26 January, 2016

Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage

DEXILANT SOLUTAB family patents

Family Patents

15. Emend patents expiration

EMEND's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6096742 MSD MERCK CO Polymorphic form of a tachykinin receptor antagonist
Jul, 2018

(5 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8258132 MSD MERCK CO Pharmaceutical composition of a tachykinin receptor antagonist
Sep, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Aug 28, 2018

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 17 December, 2015

Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of EMEND before it's drug patent expiration?
More Information on Dosage

EMEND family patents

Family Patents

16. Epivir patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5905082 VIIV HLTHCARE Crystalline oxathiolane derivatives
May, 2016

(8 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5905082

(Pediatric)

VIIV HLTHCARE Crystalline oxathiolane derivatives
Nov, 2016

(7 years ago)

US6004968 VIIV HLTHCARE Pharmaceutical compositions containing lamivudine
Mar, 2018

(6 years ago)

US6004968

(Pediatric)

VIIV HLTHCARE Pharmaceutical compositions containing lamivudine
Sep, 2018

(5 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-147) Mar 23, 2018

Drugs and Companies using LAMIVUDINE ingredient

Market Authorisation Date: 17 November, 1995

Treatment: NA

Dosage: SOLUTION;ORAL

More Information on Dosage

EPIVIR family patents

Family Patents

17. Flonase Sensimist Allergy Relief patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7101866 HALEON US HOLDINGS Anti-inflammatory androstane derivative
Aug, 2021

(2 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6858596 HALEON US HOLDINGS Formulation containing anti-inflammatory androstane derivative
Aug, 2021

(2 years ago)

US7541350 HALEON US HOLDINGS Formulation containing anti-inflammatory androstane derivative
Aug, 2021

(2 years ago)

US9320862 HALEON US HOLDINGS Fluid dispensing device
Nov, 2024

(5 months from now)

US8752543 HALEON US HOLDINGS Fluid dispensing device
Apr, 2026

(1 year, 10 months from now)

US8062264 HALEON US HOLDINGS Fluid dispensing device
Apr, 2026

(1 year, 10 months from now)

US8347879 HALEON US HOLDINGS Fluid dispensing device
Jul, 2028

(4 years from now)

US8147461 HALEON US HOLDINGS Fluid dispensing device
Oct, 2028

(4 years from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 02 August, 2016

Treatment: Otc use: allergy symptom reliever; Temporarily relieves these symptoms due to hay fever or other upper respiratory allergies; Nasal congestion, runny nose, sneezing, itchy nose, and (itchy water eyes ...

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

FLONASE SENSIMIST ALLERGY RELIEF family patents

Family Patents

18. Gadavist patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5980864 BAYER HLTHCARE 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them
Nov, 2021

(2 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5980864 BAYER HLTHCARE 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them
Nov, 2016

(7 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-801) Jul 12, 2022
New Indication(I-688) Jun 11, 2017
New Chemical Entity Exclusivity(NCE) Mar 14, 2016
New Indication(I-731) Apr 27, 2019

Drugs and Companies using GADOBUTROL ingredient

NCE-1 date: 15 March, 2015

Market Authorisation Date: 18 December, 2013

Treatment: Contrast agent for magnetic resonance imaging

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

GADAVIST family patents

Family Patents

19. Gilenya patents expiration

GILENYA's oppositions filed in EPO
GILENYA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5604229 NOVARTIS 2-amino-1,3-propanediol compound and immunosuppressant
Feb, 2019

(5 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5604229 NOVARTIS 2-amino-1,3-propanediol compound and immunosuppressant
Feb, 2014

(10 years ago)

US6004565 NOVARTIS Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties
Sep, 2017

(6 years ago)

US5604229

(Pediatric)

NOVARTIS 2-amino-1,3-propanediol compound and immunosuppressant
Aug, 2019

(4 years ago)

US8324283 NOVARTIS Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol
Mar, 2026

(1 year, 10 months from now)

US8324283

(Pediatric)

NOVARTIS Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol
Sep, 2026

(2 years from now)

US9187405 NOVARTIS S1P receptor modulators for treating relasping-remitting multiple sclerosis
Jun, 2027

(3 years from now)

US10543179 NOVARTIS Dosage regimen of an S1P receptor modulator
Dec, 2027

(3 years from now)

US9187405

(Pediatric)

NOVARTIS S1P receptor modulators for treating relasping-remitting multiple sclerosis
Dec, 2027

(3 years from now)

US9592208 NOVARTIS Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
Mar, 2032

(7 years from now)

US9592208

(Pediatric)

NOVARTIS Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
Sep, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) May 11, 2021
New Patient Population(NPP) May 11, 2021
Pediatric Exclusivity(PED) Nov 11, 2021
M(M-106) Jul 20, 2014
New Chemical Entity Exclusivity(NCE) Sep 21, 2015

Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient

NCE-1 date: 11 November, 2020

Market Authorisation Date: 11 May, 2018

Treatment: Treatment of autoimmune disease; Treatment of relapsing-remitting sclerosis (ms); Treatment of relapsing remitting multiple sclerosis by determining varicella zoster virus (vzv) status and vaccinating...

Dosage: CAPSULE;ORAL

How can I launch a generic of GILENYA before it's drug patent expiration?
More Information on Dosage

GILENYA family patents

Family Patents

20. Iressa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5770599 ASTRAZENECA Quinazoline derivatives
May, 2017

(7 years ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Jul 13, 2022
New Product(NP) Jul 13, 2018
Orphan Drug Exclusivity(ODE-95) Jul 13, 2022

Drugs and Companies using GEFITINIB ingredient

Market Authorisation Date: 13 July, 2015

Treatment: First-line treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutation...

Dosage: TABLET;ORAL

More Information on Dosage

IRESSA family patents

Family Patents

21. Jadenu Sprinkle patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6465504 NOVARTIS Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
Apr, 2019

(5 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-241) Jul 24, 2022
M(M-239) Dec 12, 2021
M(M-263) Jul 23, 2023

Drugs and Companies using DEFERASIROX ingredient

Market Authorisation Date: 18 May, 2017

Treatment: NA

Dosage: GRANULE;ORAL

More Information on Dosage

JADENU SPRINKLE family patents

Family Patents

22. Juxtapid patents expiration

JUXTAPID's oppositions filed in EPO
JUXTAPID IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5712279 CHIESI Inhibitors of microsomal triglyceride transfer protein and method
Feb, 2020

(4 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5712279 CHIESI Inhibitors of microsomal triglyceride transfer protein and method
Feb, 2015

(9 years ago)

US5739135 CHIESI Inhibitors of microsomal triglyceride transfer protein and method
Apr, 2015

(9 years ago)

US6492365 CHIESI Microsomal triglyceride transfer protein
Dec, 2019

(4 years ago)

US8618135 CHIESI Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Mar, 2025

(9 months from now)

US9265758 CHIESI Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Mar, 2025

(9 months from now)

US9364470 CHIESI Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Mar, 2025

(9 months from now)

US9433617 CHIESI Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Mar, 2025

(9 months from now)

US9861622 CHIESI Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Mar, 2025

(9 months from now)

US10016404 CHIESI Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Mar, 2025

(9 months from now)

US10555938 CHIESI Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Mar, 2025

(9 months from now)

US7932268 CHIESI Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Aug, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Dec 21, 2019
New Chemical Entity Exclusivity(NCE) Dec 21, 2017
Orphan Drug Exclusivity(ODE-36) Dec 21, 2019

Drugs and Companies using LOMITAPIDE MESYLATE ingredient

NCE-1 date: 21 December, 2016

Market Authorisation Date: 21 December, 2012

Treatment: Treatment of hypercholesterolemia, hyperlipidemia and hyperlipoproteinemia in patients with homozygous familial hypercholesterolemia; Treatment of hypercholesterolemia by decreasing the amount or acti...

Dosage: CAPSULE;ORAL

More Information on Dosage

JUXTAPID family patents

Family Patents

23. Lexiscan patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE47351 ASTELLAS 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
Jun, 2019

(4 years ago)

US8106183 ASTELLAS Process for preparing an A2A-adenosine receptor agonist and its polymorphs
Feb, 2027

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8536150 ASTELLAS Methods of myocardial perfusion imaging
Jun, 2019

(4 years ago)

US8470801 ASTELLAS Myocardial perfusion imaging methods and compositions
Jun, 2019

(4 years ago)

US8106029 ASTELLAS Use of A2A adenosine receptor agonists
Jun, 2019

(4 years ago)

US7655637 ASTELLAS N-pyrazole A2A receptor agonists
Jun, 2019

(4 years ago)

US7683037 ASTELLAS Myocardial perfusion imaging method
Jun, 2019

(4 years ago)

US7655636 ASTELLAS Use of A2A adenosine receptor agonists
Jun, 2019

(4 years ago)

US7582617 ASTELLAS Myocardial perfusion imaging method
Jun, 2019

(4 years ago)

US9289446 ASTELLAS Myocardial perfusion imaging methods and compositions
Jun, 2019

(4 years ago)

US7144872 ASTELLAS N-pyrazole A2A receptor agonists
Jun, 2019

(4 years ago)

US6642210 ASTELLAS 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
Jun, 2019

(4 years ago)

US9045519 ASTELLAS N-pyrazole A2A receptor agonists
Jun, 2019

(4 years ago)

US8183226 ASTELLAS Myocardial perfusion imaging method
Jun, 2019

(4 years ago)

US7183264 ASTELLAS N-pyrazole A2A receptor agonists
Jun, 2019

(4 years ago)

US8133879 ASTELLAS Myocardial perfusion imaging methods and compositions
Jun, 2019

(4 years ago)

US6403567 ASTELLAS N-pyrazole A2A adenosine receptor agonists
Apr, 2022

(2 years ago)

US9085601 ASTELLAS Process for preparing an A2A-adenosine receptor agonist and its polymorphs
Feb, 2027

(2 years from now)

USRE47301 ASTELLAS Process for preparing an A2A-adenosine receptor agonist and its polymorphs
Feb, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-194) Jan 17, 2020
New Chemical Entity Exclusivity(NCE) Apr 10, 2013

Drugs and Companies using REGADENOSON ingredient

NCE-1 date: 10 April, 2012

Market Authorisation Date: 10 April, 2008

Treatment: Method of myocardial imaging; Method for stimulating coronary vasodilation for purposes of imaging the heart; A method of myocardial perfusion imaging and increasing coronary blood flow; Method of pro...

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of LEXISCAN before it's drug patent expiration?
More Information on Dosage

LEXISCAN family patents

Family Patents

24. Lumason patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5686060 BRACCO Stable microbubble suspensions comprising saturated phospholipids for ultrasound echography
Nov, 2019

(4 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10232061 BRACCO Freeze-dried formulation for gas-filled microvesicles
Jul, 2038

(14 years from now)

US10335502 BRACCO Freeze-dried formulation for gas-filled microvesicles
Jul, 2038

(14 years from now)

US11723869 BRACCO Freeze-dried product and gas-filled microvesicles suspension
May, 2039

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-728) Mar 31, 2019
New Chemical Entity Exclusivity(NCE) Oct 10, 2019
New Patient Population(NPP) Nov 13, 2022

Drugs and Companies using SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES ingredient

NCE-1 date: 10 October, 2018

Market Authorisation Date: 15 October, 2014

Treatment: Use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions

Dosage: FOR SUSPENSION;INTRAVENOUS

More Information on Dosage

LUMASON family patents

Family Patents

25. Lyrica Cr patents expiration

LYRICA CR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6197819 UPJOHN Gamma amino butyric acid analogs and optical isomers
Dec, 2018

(5 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE41920 UPJOHN Isobutylgaba and its derivatives for the treatment of pain
Dec, 2018

(5 years ago)

US6197819

(Pediatric)

UPJOHN Gamma amino butyric acid analogs and optical isomers
Jun, 2019

(4 years ago)

USRE41920

(Pediatric)

UPJOHN Isobutylgaba and its derivatives for the treatment of pain
Jun, 2019

(4 years ago)

US8945620 UPJOHN Solid pharmaceutical compositions containing pregabalin
Nov, 2026

(2 years from now)

US10022447 UPJOHN Solid pharmaceutical compositions containing pregabalin
Nov, 2026

(2 years from now)

US9144559 UPJOHN Solid pharmaceutical compositions containing pregabalin
Nov, 2026

(2 years from now)

US9144559

(Pediatric)

UPJOHN Solid pharmaceutical compositions containing pregabalin
May, 2027

(2 years from now)

US10022447

(Pediatric)

UPJOHN Solid pharmaceutical compositions containing pregabalin
May, 2027

(2 years from now)

US8945620

(Pediatric)

UPJOHN Solid pharmaceutical compositions containing pregabalin
May, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 11, 2020
Pediatric Exclusivity(PED) Apr 11, 2021

Drugs and Companies using PREGABALIN ingredient

Market Authorisation Date: 11 October, 2017

Treatment: Treatment of postherpetic neuralgia; Treatment of neuropathic pain associated with diabetic peripheral neuropathy

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of LYRICA CR before it's drug patent expiration?
More Information on Dosage

LYRICA CR family patents

Family Patents

26. Macrilen patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6861409 NOVO Growth hormone secretagogues
Aug, 2022

(1 year, 9 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8192719 NOVO Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds
Oct, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-170) Dec 20, 2024
New Chemical Entity Exclusivity(NCE) Dec 20, 2022

Drugs and Companies using MACIMORELIN ACETATE ingredient

NCE-1 date: 20 December, 2021

Market Authorisation Date: 20 December, 2017

Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

MACRILEN family patents

Family Patents

27. Myrbetriq Granules patents expiration

MYRBETRIQ GRANULES IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6346532 APGDI Amide derivatives or salts thereof
Mar, 2022

(2 years ago)

US7342117 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(6 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6346532

(Pediatric)

APGDI Amide derivatives or salts thereof
Sep, 2022

(1 year, 7 months ago)

US7982049 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(6 months ago)

US7342117

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(20 days ago)

US7982049

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(20 days ago)

US10058536 APGDI Pharmaceutical composition containing mirabegron
Mar, 2036

(11 years from now)

US10058536

(Pediatric)

APGDI Pharmaceutical composition containing mirabegron
Oct, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 25, 2024
Pediatric Exclusivity(PED) Sep 25, 2024

Drugs and Companies using MIRABEGRON ingredient

Market Authorisation Date: 25 March, 2021

Treatment: Treatment of neurogenic detrusor overactivity (ndo) in pediatric patients aged 3 years and older by administration of an extended-release suspension formulation of mirabegron

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

MYRBETRIQ GRANULES family patents

Family Patents

28. Nexium 24hr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5900424 ASTRAZENECA LP Omeprazole magnesium salt form
May, 2016

(8 years ago)

US7411070 ASTRAZENECA LP Form of S-omeprazole
May, 2018

(6 years ago)

US6369085 ASTRAZENECA LP Form of S-omeprazole
May, 2018

(6 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5900424

(Pediatric)

ASTRAZENECA LP Omeprazole magnesium salt form
Nov, 2016

(7 years ago)

US7411070

(Pediatric)

ASTRAZENECA LP Form of S-omeprazole
Nov, 2018

(5 years ago)

US6369085

(Pediatric)

ASTRAZENECA LP Form of S-omeprazole
Nov, 2018

(5 years ago)

US6428810 ASTRAZENECA LP Pharmaceutical formulation comprising omeprazole
Nov, 2019

(4 years ago)

US6428810

(Pediatric)

ASTRAZENECA LP Pharmaceutical formulation comprising omeprazole
May, 2020

(4 years ago)

Drugs and Companies using ESOMEPRAZOLE MAGNESIUM ingredient

Market Authorisation Date: 23 November, 2015

Treatment: Method of treating frequent heartburn by administering an esomeprazole magnesium formulation as claimed; Method of treating frequent heartburn by administering an esomeprazole magnesium as claimed; Me...

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of NEXIUM 24HR before it's drug patent expiration?
More Information on Dosage

NEXIUM 24HR family patents

Family Patents

29. Norditropin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5633352 NOVO NORDISK INC Biosynthetic human growth hormone
May, 2014

(10 years ago)

US5849704 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2015

(8 years ago)

US5849700 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2015

(8 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-572) Oct 31, 2011
Orphan Drug Exclusivity(ODE) May 31, 2014

Drugs and Companies using SOMATROPIN RECOMBINANT ingredient

Market Authorisation Date: 23 January, 2015

Treatment: The long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children

Dosage: INJECTABLE;INJECTION

More Information on Dosage

NORDITROPIN family patents

Family Patents

30. Norditropin Flexpro patents expiration

NORDITROPIN FLEXPRO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5849704 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2015

(8 years ago)

US5849700 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2015

(8 years ago)

US8841252 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2017

(6 years ago)

US6716198 NOVO NORDISK INC Injection device
Jun, 2021

(2 years ago)

US9486588 NOVO NORDISK INC Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8672898 NOVO NORDISK INC Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US6899699 NOVO NORDISK INC Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8579869 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(10 months ago)

US7762994 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
May, 2024

(a day ago)

US8684969 NOVO NORDISK INC Injection device with torsion spring and rotatable display
Oct, 2025

(1 year, 4 months from now)

US10376652 NOVO NORDISK INC Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US10357616 NOVO NORDISK INC Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 7 months from now)

US9108002 NOVO NORDISK INC Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US9861757 NOVO NORDISK INC Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 7 months from now)

US9616180 NOVO NORDISK INC Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US10220155 NOVO NORDISK INC Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

US8920383 NOVO NORDISK INC Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US9775953 NOVO NORDISK INC Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US7686786 NOVO NORDISK INC Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

USRE46363 NOVO NORDISK INC Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US9687611 NOVO NORDISK INC Injection device with torsion spring and rotatable display
Feb, 2027

(2 years from now)

US9457154 NOVO NORDISK INC Injection device with an end of dose feedback mechanism
Sep, 2027

(3 years from now)

US9132239 NOVO NORDISK INC Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-572) Oct 31, 2011
Orphan Drug Exclusivity(ODE) May 31, 2014

Drugs and Companies using SOMATROPIN RECOMBINANT ingredient

Market Authorisation Date: 23 January, 2015

Treatment: Treatment of disorders responsive to growth hormone

Dosage: INJECTABLE;INJECTION

More Information on Dosage

NORDITROPIN FLEXPRO family patents

Family Patents

31. Norditropin Flexpro patents expiration

NORDITROPIN FLEXPRO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5849704 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2015

(8 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5849700 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2015

(8 years ago)

US8841252 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2017

(6 years ago)

US9486588 NOVO NORDISK INC Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US6899699 NOVO NORDISK INC Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8672898 NOVO NORDISK INC Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8579869 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(10 months ago)

US7762994 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
May, 2024

(a day ago)

US8684969 NOVO NORDISK INC Injection device with torsion spring and rotatable display
Oct, 2025

(1 year, 4 months from now)

US10376652 NOVO NORDISK INC Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US9861757 NOVO NORDISK INC Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 7 months from now)

US9616180 NOVO NORDISK INC Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US10357616 NOVO NORDISK INC Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 7 months from now)

US9108002 NOVO NORDISK INC Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US8920383 NOVO NORDISK INC Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US10220155 NOVO NORDISK INC Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

US9775953 NOVO NORDISK INC Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US7686786 NOVO NORDISK INC Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

USRE46363 NOVO NORDISK INC Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US9687611 NOVO NORDISK INC Injection device with torsion spring and rotatable display
Feb, 2027

(2 years from now)

US9457154 NOVO NORDISK INC Injection device with an end of dose feedback mechanism
Sep, 2027

(3 years from now)

US9132239 NOVO NORDISK INC Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-572) Oct 31, 2011
Orphan Drug Exclusivity(ODE) May 31, 2014

Drugs and Companies using SOMATROPIN ingredient

Market Authorisation Date: 23 January, 2015

Treatment: Treatment of disorders responsive to growth hormone

Dosage: INJECTABLE;INJECTION

More Information on Dosage

NORDITROPIN FLEXPRO family patents

Family Patents

32. Norditropin Nordiflex patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5849704 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2015

(8 years ago)

US5849700 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2015

(8 years ago)

US8841252 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2017

(6 years ago)

USRE43834 NOVO NORDISK INC Injection syringe
Jan, 2019

(5 years ago)

US6235004 NOVO NORDISK INC Injection syringe
Jan, 2019

(5 years ago)

US6004297 NOVO NORDISK INC Injection syringe
Jan, 2019

(5 years ago)

USRE41956 NOVO NORDISK INC Dose setting limiter
Jan, 2021

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-572) Oct 31, 2011
Orphan Drug Exclusivity(ODE) May 31, 2014

Drugs and Companies using SOMATROPIN RECOMBINANT ingredient

Market Authorisation Date: 23 January, 2015

Treatment: The long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children

Dosage: INJECTABLE;INJECTION

More Information on Dosage

NORDITROPIN NORDIFLEX family patents

Family Patents

33. Saxenda patents expiration

SAXENDA's oppositions filed in EPO
SAXENDA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6458924 NOVO Derivatives of GLP-1 analogs
Aug, 2017

(6 years ago)

US7235627 NOVO Derivatives of GLP-1 analogs
Aug, 2017

(6 years ago)

US6268343 NOVO Derivatives of GLP-1 analogs
Aug, 2022

(1 year, 9 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6899699 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US9486588 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8672898 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8846618 NOVO Stable formulation of modified GLP-1
Jun, 2022

(1 year, 10 months ago)

US6899699

(Pediatric)

NOVO Automatic injection device with reset feature
Jul, 2022

(1 year, 10 months ago)

US9486588

(Pediatric)

NOVO Automatic injection device with reset feature
Jul, 2022

(1 year, 10 months ago)

US8672898

(Pediatric)

NOVO Automatic injection device with reset feature
Jul, 2022

(1 year, 10 months ago)

US8846618

(Pediatric)

NOVO Stable formulation of modified GLP-1
Dec, 2022

(1 year, 4 months ago)

US6268343

(Pediatric)

NOVO Derivatives of GLP-1 analogs
Feb, 2023

(1 year, 3 months ago)

US8579869 NOVO Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(10 months ago)

US8579869

(Pediatric)

NOVO Needle mounting system and a method for mounting a needle assembly
Dec, 2023

(4 months ago)

US7762994 NOVO Needle mounting system and a method for mounting a needle assembly
May, 2024

(a day ago)

US7762994

(Pediatric)

NOVO Needle mounting system and a method for mounting a needle assembly
Nov, 2024

(5 months from now)

US8114833 NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(1 year, 2 months from now)

US8684969 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(1 year, 4 months from now)

US11446443 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(1 year, 4 months from now)

US9861757 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 7 months from now)

US9616180 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US11311679 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US10357616 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 7 months from now)

US10376652 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US9108002 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 8 months from now)

US8114833

(Pediatric)

NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Feb, 2026

(1 year, 8 months from now)

US8684969

(Pediatric)

NOVO Injection device with torsion spring and rotatable display
Apr, 2026

(1 year, 10 months from now)

US10220155 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

US11097063 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

US9775953 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US8920383 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US9861757

(Pediatric)

NOVO Injection device with an end of dose feedback mechanism
Jul, 2026

(2 years from now)

US9616180

(Pediatric)

NOVO Automatic injection device with a top release mechanism
Jul, 2026

(2 years from now)

US9108002

(Pediatric)

NOVO Automatic injection device with a top release mechanism
Jul, 2026

(2 years from now)

US7686786 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

USRE46363 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US8920383

(Pediatric)

NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jan, 2027

(2 years from now)

US9775953

(Pediatric)

NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jan, 2027

(2 years from now)

US10220155

(Pediatric)

NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jan, 2027

(2 years from now)

USRE46363

(Pediatric)

NOVO Dial-down mechanism for wind-up pen
Feb, 2027

(2 years from now)

US9687611 NOVO Injection device with torsion spring and rotatable display
Feb, 2027

(2 years from now)

US9687611

(Pediatric)

NOVO Injection device with torsion spring and rotatable display
Aug, 2027

(3 years from now)

US9457154 NOVO Injection device with an end of dose feedback mechanism
Sep, 2027

(3 years from now)

US9457154

(Pediatric)

NOVO Injection device with an end of dose feedback mechanism
Mar, 2028

(3 years from now)

US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)

US9132239

(Pediatric)

NOVO Dial-down mechanism for wind-up pen
Aug, 2032

(8 years from now)

US9968659 NOVO Liraglutide in cardiovascular conditions
Jan, 2037

(12 years from now)

US9968659

(Pediatric)

NOVO Liraglutide in cardiovascular conditions
Jul, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 04, 2023
New Chemical Entity Exclusivity(NCE) Jan 25, 2015
New Product(NP) Jan 25, 2017

Drugs and Companies using LIRAGLUTIDE ingredient

NCE-1 date: 25 January, 2014

Market Authorisation Date: 23 December, 2014

Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease; Method for chronic weight management by treating obesity

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of SAXENDA before it's drug patent expiration?
More Information on Dosage

SAXENDA family patents

Family Patents

34. Selzentry patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6586430 VIIV HLTHCARE CCR5 modulators
Dec, 2019

(4 years ago)

US7576097 VIIV HLTHCARE Tropane derivatives useful in therapy
May, 2021

(3 years ago)

US6667314 VIIV HLTHCARE Tropane derivatives useful in therapy
Aug, 2021

(2 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6586430 VIIV HLTHCARE CCR5 modulators
Dec, 2019

(4 years ago)

US7576097 VIIV HLTHCARE Tropane derivatives useful in therapy
May, 2021

(3 years ago)

US6667314 VIIV HLTHCARE Tropane derivatives useful in therapy
Aug, 2021

(2 years ago)

US7576097

(Pediatric)

VIIV HLTHCARE Tropane derivatives useful in therapy
Nov, 2021

(2 years ago)

US6667314

(Pediatric)

VIIV HLTHCARE Tropane derivatives useful in therapy
Feb, 2022

(2 years ago)

US7368460 VIIV HLTHCARE Tropane derivatives useful in therapy
Nov, 2022

(1 year, 5 months ago)

US7368460

(Pediatric)

VIIV HLTHCARE Tropane derivatives useful in therapy
May, 2023

(a year ago)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) May 28, 2013
New Strength(NS) Nov 04, 2019
New Chemical Entity Exclusivity(NCE) Aug 06, 2012

Drugs and Companies using MARAVIROC ingredient

NCE-1 date: 07 August, 2011

Market Authorisation Date: 04 November, 2016

Treatment: Method of treating patients infected with ccr5-tropic hiv-1

Dosage: TABLET;ORAL; SOLUTION;ORAL

How can I launch a generic of SELZENTRY before it's drug patent expiration?
More Information on Dosage

SELZENTRY family patents

Family Patents

35. Soliqua 100/33 patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE45313 SANOFI-AVENTIS US Exendin variant peptides
Jul, 2020

(3 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9827379 SANOFI-AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Mar, 2024

(2 months ago)

US9775954 SANOFI-AVENTIS US Pen-type injector
Mar, 2024

(2 months ago)

US9604008 SANOFI-AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Mar, 2024

(2 months ago)

US9408979 SANOFI-AVENTIS US Pen-type injector
Mar, 2024

(2 months ago)

US9233211 SANOFI-AVENTIS US Relating to a pen-type injector
Mar, 2024

(2 months ago)

US9526844 SANOFI-AVENTIS US Pen-type injector
Mar, 2024

(2 months ago)

US8603044 SANOFI-AVENTIS US Pen-type injector
Mar, 2024

(2 months ago)

US9610409 SANOFI-AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Mar, 2024

(2 months ago)

US8556864 SANOFI-AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Mar, 2024

(2 months ago)

US9011391 SANOFI-AVENTIS US Pen-type injector
Mar, 2024

(a month ago)

US8992486 SANOFI-AVENTIS US Pen-type injector
Jun, 2024

(11 days from now)

US9604009 SANOFI-AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Aug, 2024

(2 months from now)

US9533105 SANOFI-AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Aug, 2024

(2 months from now)

US9623189 SANOFI-AVENTIS US Relating to drive mechanisms suitable for use in drug delivery devices
Aug, 2024

(2 months from now)

US9561331 SANOFI-AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Aug, 2024

(3 months from now)

US8512297 SANOFI-AVENTIS US Pen-type injector
Sep, 2024

(3 months from now)

US8679069 SANOFI-AVENTIS US Pen-type injector
Apr, 2025

(10 months from now)

US7918833 SANOFI-AVENTIS US Pen-type injector
Sep, 2027

(3 years from now)

US10117909 SANOFI-AVENTIS US Combination of an insulin and a GLP-1 agonist
Oct, 2029

(5 years from now)

US9526764 SANOFI-AVENTIS US Combination of an insulin and a GLP-1-agonist
Oct, 2029

(5 years from now)

US10029011 SANOFI-AVENTIS US Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
Nov, 2030

(6 years from now)

US9707176 SANOFI-AVENTIS US Pharmaceutical composition comprising a GLP-1 agonist and methionine
Nov, 2030

(6 years from now)

US9821032 SANOFI-AVENTIS US Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
May, 2032

(7 years from now)

US9717852 SANOFI-AVENTIS US Cartridge holder and pen-type injector
Apr, 2033

(8 years from now)

US9950039 SANOFI-AVENTIS US Insulin glargine/lixisenatide fixed ratio formulation
Dec, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Nov 21, 2019
New Chemical Entity Exclusivity(NCE) Jul 27, 2021

Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient

NCE-1 date: 27 July, 2020

Market Authorisation Date: 21 November, 2016

Treatment: Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a rotating drive sleeve; Improvement in glycemic control in adults with type 2 diabetes mellitus by use of a...

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

SOLIQUA 100/33 family patents

Family Patents

36. Spiriva Respimat patents expiration

SPIRIVA RESPIMAT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE39820 BOEHRINGER INGELHEIM Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
Jan, 2018

(6 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7246615 BOEHRINGER INGELHEIM Atomising nozzle and filter and spray generating device
May, 2016

(7 years ago)

US6176242 BOEHRINGER INGELHEIM Method of treating manic depression by brain infusion
May, 2016

(7 years ago)

US6176442 BOEHRINGER INGELHEIM Device for mounting a component exposed to a pressurized fluid
May, 2016

(7 years ago)

US7104470 BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Oct, 2016

(7 years ago)

US5964416 BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Oct, 2016

(7 years ago)

US6726124 BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Oct, 2016

(7 years ago)

US7246615

(Pediatric)

BOEHRINGER INGELHEIM Atomising nozzle and filter and spray generating device
Dec, 2016

(7 years ago)

US6176442

(Pediatric)

BOEHRINGER INGELHEIM Device for mounting a component exposed to a pressurized fluid
Dec, 2016

(7 years ago)

US6453795 BOEHRINGER INGELHEIM Locking mechanism for a spring-actuated device
Dec, 2016

(7 years ago)

US6149054 BOEHRINGER INGELHEIM Mechanical counter for a metering apparatus
Dec, 2016

(7 years ago)

US5964416

(Pediatric)

BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Apr, 2017

(7 years ago)

US7104470

(Pediatric)

BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Apr, 2017

(7 years ago)

US6726124

(Pediatric)

BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Apr, 2017

(7 years ago)

US6453795

(Pediatric)

BOEHRINGER INGELHEIM Locking mechanism for a spring-actuated device
Jun, 2017

(6 years ago)

US6149054

(Pediatric)

BOEHRINGER INGELHEIM Mechanical counter for a metering apparatus
Jun, 2017

(6 years ago)

USRE39820

(Pediatric)

BOEHRINGER INGELHEIM Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
Jul, 2018

(5 years ago)

US6977042 BOEHRINGER INGELHEIM Microstructured filter
Aug, 2018

(5 years ago)

US6846413 BOEHRINGER INGELHEIM Microstructured filter
Aug, 2018

(5 years ago)

US7802568 BOEHRINGER INGELHEIM Cartridge for a liquid
Feb, 2019

(5 years ago)

US6846413

(Pediatric)

BOEHRINGER INGELHEIM Microstructured filter
Feb, 2019

(5 years ago)

US6977042

(Pediatric)

BOEHRINGER INGELHEIM Microstructured filter
Feb, 2019

(5 years ago)

US7802568

(Pediatric)

BOEHRINGER INGELHEIM Cartridge for a liquid
Aug, 2019

(4 years ago)

US6988496 BOEHRINGER INGELHEIM Cartridge for a liquid
Feb, 2020

(4 years ago)

US6988496

(Pediatric)

BOEHRINGER INGELHEIM Cartridge for a liquid
Aug, 2020

(3 years ago)

US7988001 BOEHRINGER INGELHEIM Container provided with a pressure equalization opening
Aug, 2021

(2 years ago)

US7988001

(Pediatric)

BOEHRINGER INGELHEIM Container provided with a pressure equalization opening
Feb, 2022

(2 years ago)

US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(3 months from now)

US7284474

(Pediatric)

BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Feb, 2025

(9 months from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(1 year, 1 day from now)

US7896264

(Pediatric)

BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
Nov, 2025

(1 year, 6 months from now)

US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Oct, 2026

(2 years from now)

US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2027

(2 years from now)

US7396341

(Pediatric)

BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Apr, 2027

(2 years from now)

US9027967

(Pediatric)

BOEHRINGER INGELHEIM Device for clamping a fluidic component
Oct, 2027

(3 years from now)

US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2028

(3 years from now)

US7837235

(Pediatric)

BOEHRINGER INGELHEIM Device for clamping a fluidic component
Sep, 2028

(4 years from now)

US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Oct, 2030

(6 years from now)

US8733341

(Pediatric)

BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Apr, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 24, 2017
New Patient Population(NPP) Feb 15, 2020
Pediatric Exclusivity(PED) Aug 15, 2020

Drugs and Companies using TIOTROPIUM BROMIDE ingredient

Market Authorisation Date: 15 September, 2015

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

How can I launch a generic of SPIRIVA RESPIMAT before it's drug patent expiration?